Cerus Corporation announced preliminary product revenue for the fourth quarter and full-year 2025, showcasing its financial performance for the period.
The company's full-year 2025 product revenue amounted to $206.1 million, demonstrating a 14% increase over the previous year. Looking ahead, Cerus anticipates revenue to surge to a range of $224 million to $228 million in 2026, underpinning its optimistic growth trajectory.
In addition to financial achievements, Cerus emphasized its success in enhancing patient access to INTERCEPT treated blood components on a global scale, reflecting its commitment to innovation and blood safety.
Financial Results
Cerus achieved a notable milestone in 2025 with full-year product revenue reaching $206.1 million, marking a substantial 14% growth compared to 2024, indicating positive market reception for its offerings.
Growth Projection
The company's forward-looking projections for 2026 signal a promising growth trajectory, with anticipated revenue growth rates between 9% and 11%. Cerus expects to generate revenue within the range of $224 million to $228 million in 2026, reflecting its strategic focus on expanding market share and driving revenue growth.
Product Milestones
Cerus has outlined key milestones for 2026, including the submission of a PMA application for INT200 and the release of results from the Phase 3 RedeS study. These milestones underscore the company's commitment to product innovation and regulatory advancements, enhancing its competitive position.
- Cerus Corporation's robust 14% increase in full-year 2025 product revenue signifies its effective commercial execution and market demand for its products, positioning the company as a key player in the industry.
- The projected revenue growth range of 9%-11% for 2026 underscores Cerus's resilience and strategic initiatives to drive sustained revenue expansion, fostering investor confidence and reinforcing its market presence.
Cerus Corporation's impressive financial performance in 2025 underscores a year of strong growth, supported by solid revenue figures and strategic advancements. With a positive outlook for 2026 and a focus on innovation and regulatory milestones, Cerus is well-positioned to capitalize on market opportunities and continue its growth trajectory in the blood safety segment and beyond.